

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/000340

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/37

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, COMPENDEX, INSPEC, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STEPHAN CARSTEN ET AL: "Quantitative analysis of kallikrein 15 gene expression in prostate tissue." JOURNAL OF UROLOGY, vol. 169, no. 1, January 2003 (2003-01), pages 361-364, XP002326735 ISSN: 0022-5347 page 362, left-hand column; page 363, "Discussion"	22
X	WO 02/097438 A (MOUNT SINAI HOSPITAL; DIAMANDIS, ELEFTHERIOS) 5 December 2002 (2002-12-05) page 3, line 20 - page 4, line 2; page 12, lines 9 - page 14, line 2; claims 4 and 22 ----- -/-	19-23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the International search

4 May 2005

Date of mailing of the International search report

28.06.2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hennard, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/000340

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>YUSEF G M ET AL: "THE NEW HUMAN TISSUE KALLIKREIN GENE FAMILY: STRUCTURE, FUNCTION AND ASSOCIATION TO DISEASE" ENDOCRINE REVIEWS, BALTIMORE, MD, US, vol. 22, no. 2, April 2001 (2001-04), pages 184-204, XP001104999 page 197, table 9 and part XI</p>	1-26
A	<p>YAYAMA K ET AL: "Tissue kallikrein is synthesized and secreted by human vascular endothelial cells" BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1593, no. 2-3, 17 February 2003 (2003-02-17), pages 231-238, XP004409779 ISSN: 0167-4889 page 231, Introduction</p>	1-26
P,X	<p>WO 2004/029285 A (MOUNT SINAI HOSPITAL; YUSEF, GEORGE; DIAMANDIS, ELEFTERIOS, P) 8 April 2004 (2004-04-08) claims 23-31</p>	18-23
X	<p>WO 02/14485 A (MOUNT SINAI HOSPITAL; YUSEF, GEORGE, M; DIAMANDIS, ELEFTERIOS, P) 21 February 2002 (2002-02-21) cited in the application page 21, paragraph 4.3; claims</p>	19-23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2005/000340

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 26 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-26 (part)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-26(part)

Method of screening for therapeutical agents useful in the treatment of cardiovascular diseases; method for diagnosing cardiovascular diseases; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of cardiovascular diseases; pharmaceutical composition comprising a KLK15 polynucleotide for the treatment of cardiovascular diseases; method for the preparation of a pharmaceutical composition for the treatment of cardiovascular diseases.

2. claims: 1-26(part)

Method of screening for therapeutical agents useful in the treatment of cancer; method for diagnosing cancer; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of cancer; pharmaceutical composition comprising a KLK15 polynucleotide; method for the preparation of a pharmaceutical composition for the treatment of cancer.

3. claims: 1-26(part)

Method of screening for therapeutical agents useful in the treatment of gastro-enterological diseases; method for diagnosing gastro-enterological diseases; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of gastro-enterological diseases; pharmaceutical composition comprising a KLK15 polynucleotide; method for the preparation of a pharmaceutical composition for the treatment of gastro-enterological diseases.

4. claims: 1-26(part)

Method of screening for therapeutical agents useful in the treatment of inflammation; method for diagnosing inflammation; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of inflammation; pharmaceutical composition comprising a KLK15 polynucleotide; method for the preparation of a pharmaceutical composition for the treatment of inflammation.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. claims: 1-26(part)

Method of screening for therapeutical agents useful in the treatment of metabolic diseases; method for diagnosing metabolic diseases; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of metabolic diseases; pharmaceutical composition comprising a KLK15 polynucleotide for the treatment of metabolic diseases; method for the preparation of a pharmaceutical composition for the treatment of metabolic diseases.

6. claims: 1-26(part)

Method of screening for therapeutical agents useful in the treatment of haematological diseases; method for diagnosing haematological diseases; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of haematological diseases; pharmaceutical composition comprising a KLK15 polynucleotide for the treatment of haematological diseases; method for the preparation of a pharmaceutical composition for the treatment of haematological diseases.

7. claims: 1-26(part)

Method of screening for therapeutical agents useful in the treatment of respiratory diseases; method for diagnosing respiratory diseases; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of respiratory diseases; pharmaceutical composition comprising a KLK15 polynucleotide for the treatment of respiratory diseases; method for the preparation of a pharmaceutical composition for the treatment of respiratory diseases.

8. claims: 1-26(part)

Method of screening for therapeutical agents useful in the treatment of neurological diseases; method for diagnosing neurological diseases; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of neurological diseases; pharmaceutical composition comprising a KLK15 polynucleotide for the treatment of neurological diseases; method for the preparation of a pharmaceutical composition for the treatment of neurological diseases.

9. claims: 1-26(part)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Method of screening for therapeutical agents useful in the treatment of reproduction disorders; method for diagnosing reproduction disorders; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of reproduction disorders; pharmaceutical composition comprising a KLK15 polynucleotide for the treatment of reproduction disorders; method for the preparation of a pharmaceutical composition for the treatment of reproduction disorders.

10. claims: 1-26(part)

Method of screening for therapeutical agents useful in the treatment of urological diseases; method for diagnosing urological diseases; pharmaceutical compositions comprising agents which bind/regulate the activity of or comprising a KLK15 polypeptide for the treatment of urological diseases; pharmaceutical composition comprising a KLK15 polynucleotide for the treatment of urological diseases; method for the preparation of a pharmaceutical composition for the treatment of urological diseases.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 2005/000340

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02097438	A	05-12-2002	WO 02097438 A1	05-12-2002
			CA 2448355 A1	05-12-2002
			EP 1390756 A1	25-02-2004
			JP 2004530884 T	07-10-2004
			US 2004203012 A1	14-10-2004
WO 2004029285	A	08-04-2004	AU 2003271456 A1	19-04-2004
			WO 2004029285 A2	08-04-2004
			CA 2499261 A1	08-04-2004
WO 0214485	A	21-02-2002	AU 8738401 A	25-02-2002
			WO 0214485 A2	21-02-2002
			CA 2418422 A1	21-02-2002
			EP 1309703 A2	14-05-2003
			JP 2004505649 T	26-02-2004
			US 2004058342 A1	25-03-2004